CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

Over the last 20 years, we’ve seen major strides in the treatment options for major depressive disorder. We now understand that depression isn’t the same for everyone. The idea is to identify ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder. The San Diego ...